AU2002302555B2 - EF-Tu binding agent as antibacterial agent - Google Patents

EF-Tu binding agent as antibacterial agent Download PDF

Info

Publication number
AU2002302555B2
AU2002302555B2 AU2002302555A AU2002302555A AU2002302555B2 AU 2002302555 B2 AU2002302555 B2 AU 2002302555B2 AU 2002302555 A AU2002302555 A AU 2002302555A AU 2002302555 A AU2002302555 A AU 2002302555A AU 2002302555 B2 AU2002302555 B2 AU 2002302555B2
Authority
AU
Australia
Prior art keywords
amino acids
substances
antibacterial agent
domain
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002302555A
Other languages
English (en)
Other versions
AU2002302555A1 (en
Inventor
Frank Mayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novologix GmbH
Original Assignee
Novologix GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10129870A external-priority patent/DE10129870A1/de
Application filed by Novologix GmbH filed Critical Novologix GmbH
Publication of AU2002302555A1 publication Critical patent/AU2002302555A1/en
Application granted granted Critical
Publication of AU2002302555B2 publication Critical patent/AU2002302555B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002302555A 2001-04-30 2002-04-22 EF-Tu binding agent as antibacterial agent Ceased AU2002302555B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10121145.7 2001-04-30
DE10121145 2001-04-30
DE10129870.6 2001-06-21
DE10129870A DE10129870A1 (de) 2001-04-30 2001-06-21 Antibakterielles Mittel
PCT/EP2002/004410 WO2002087554A2 (fr) 2001-04-30 2002-04-22 Agent antibacterien

Publications (2)

Publication Number Publication Date
AU2002302555A1 AU2002302555A1 (en) 2003-04-17
AU2002302555B2 true AU2002302555B2 (en) 2007-08-23

Family

ID=26009202

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002302555A Ceased AU2002302555B2 (en) 2001-04-30 2002-04-22 EF-Tu binding agent as antibacterial agent

Country Status (17)

Country Link
EP (1) EP1397157A2 (fr)
JP (1) JP2004534016A (fr)
CN (1) CN1298739C (fr)
AU (1) AU2002302555B2 (fr)
BG (1) BG108399A (fr)
BR (1) BR0209282A (fr)
CA (1) CA2445995A1 (fr)
CZ (1) CZ20033271A3 (fr)
EE (1) EE200300530A (fr)
HU (1) HUP0401586A3 (fr)
IL (1) IL158627A0 (fr)
MX (1) MXPA03009954A (fr)
NZ (1) NZ529662A (fr)
PL (1) PL366836A1 (fr)
RU (1) RU2003134636A (fr)
SK (1) SK14792003A3 (fr)
WO (1) WO2002087554A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10229645A1 (de) * 2002-07-02 2004-05-19 Kuchenreuther, Ulrich, Dr. Zellaufschluss von Bakterien
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (fr) 2009-07-31 2017-06-06 Thar Pharma, Llc Procede de cristallisation et biodisponibilite
WO2012071517A2 (fr) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Nouvelles formes cristallines
CN105218668B (zh) * 2015-10-30 2020-03-24 山东农业大学 马耳他型布氏杆菌的EF-Tu蛋白单克隆抗体MAb及其制备方法与应用
WO2017208070A1 (fr) 2016-05-31 2017-12-07 Grünenthal GmbH Acide bisphosphonique et coformeurs avec lysine, glycine, nicotinamide pour le traitement de la polyarthrite psoriasique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466251A1 (fr) * 1990-07-10 1992-01-15 Gist-Brocades N.V. Mutants résistant à l'elfamycine
AU2717699A (en) * 1998-01-23 1999-08-09 Akzo Nobel N.V. Ef-tu mrna as a marker for viability of bacteria
US6451556B1 (en) * 1998-12-21 2002-09-17 Smithkline Beecham Corporation EF-Tu

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Heffron et al., (2000) Biochemistry vol 39, pp 37-45. *

Also Published As

Publication number Publication date
SK14792003A3 (sk) 2004-07-07
WO2002087554A3 (fr) 2003-01-30
NZ529662A (en) 2006-08-31
CA2445995A1 (fr) 2002-11-07
CN1298739C (zh) 2007-02-07
PL366836A1 (en) 2005-02-07
BR0209282A (pt) 2004-07-27
HUP0401586A3 (en) 2005-06-28
JP2004534016A (ja) 2004-11-11
IL158627A0 (en) 2004-05-12
EE200300530A (et) 2004-04-15
BG108399A (bg) 2004-08-31
CZ20033271A3 (en) 2004-06-16
CN1518455A (zh) 2004-08-04
EP1397157A2 (fr) 2004-03-17
RU2003134636A (ru) 2005-04-20
HUP0401586A2 (hu) 2004-11-29
WO2002087554B1 (fr) 2005-01-27
WO2002087554A2 (fr) 2002-11-07
MXPA03009954A (es) 2005-07-25

Similar Documents

Publication Publication Date Title
Migoń et al. Hydrocarbon stapled antimicrobial peptides
Hansen et al. Intracellular toxicity of proline-rich antimicrobial peptides shuttled into mammalian cells by the cell-penetrating peptide penetratin
Lee et al. Structure–activity relationships of de novo designed cyclic antimicrobial peptides based on gramicidin S
Rosenfeld et al. Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides
Xie et al. Novel antimicrobial peptide CPF‐C1 analogs with superior stabilities and activities against multidrug‐resistant bacteria
AU2002302555B2 (en) EF-Tu binding agent as antibacterial agent
Davlieva et al. An adaptive mutation in Enterococcus faecium LiaR associated with antimicrobial peptide resistance mimics phosphorylation and stabilizes LiaR in an activated state
Shamova et al. Minibactenecins ChBac7. Nα and ChBac7. Nβ-antimicrobial peptides from leukocytes of the goat Capra hircus
Munk et al. Synthetic analogs of anoplin show improved antimicrobial activities
Park et al. Role of proline, cysteine and a disulphide bridge in the structure and activity of the anti-microbial peptide gaegurin 5
Li et al. Effects of N‐terminal modifications on the stability of antimicrobial peptide SAMP‐A4 analogues against protease degradation
Gururaja et al. Candidacidal activity prompted by N-terminus histatin-like domain of human salivary mucin (MUC7)
Svensson et al. LL-37-induced host cell cytotoxicity depends on cellular expression of the globular C1q receptor (p33)
Walker et al. Functional complementation of staphylococcal alpha-hemolysin fragments. Overlaps, nicks, and gaps in the glycine-rich loop.
US20200172598A1 (en) Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof
Di Guilmi et al. The glycosyltransferase domain of penicillin-binding protein 2a from Streptococcus pneumoniae catalyzes the polymerization of murein glycan chains
US20040198643A1 (en) Antibacterial agent
Elfaki et al. Identification and characterization of peptides that bind the PPIase domain of Parvulin17
Thomson et al. Mapping Hsp47 binding site (s) using CNBr peptides derived from type I and type II collagen
Nakazawa et al. TNFα induces acetylation of p53 but attenuates its transcriptional activation in rheumatoid synoviocytes
Giltrap Total synthesis of teixobactin
Emran et al. A role for Yin Yang-1 (YY1) in the assembly of snRNA transcription complexes
KR102850103B1 (ko) 신경독소 역가 측정용 신규한 신경세포주
WO2006108225A1 (fr) Procede de criblage pour des composes qui modulent la proliferation cellulaire
Park et al. Synthetic diastereomeric‐antimicrobial peptide: Antibacterial activity against multiple drug resistant clinical isolates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired